Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Doctoral School of Health Sciences, Semmelweis University, Budapest, Hungary.
BMC Med. 2023 Jul 19;21(1):262. doi: 10.1186/s12916-023-02961-0.
BACKGROUND: Probiotics are often used to prevent antibiotic-induced low-diversity dysbiosis, however their effect is not yet sufficiently summarized in this regard. We aimed to investigate the effects of concurrent probiotic supplementation on gut microbiome composition during antibiotic therapy. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials reporting the differences in gut microbiome diversity between patients on antibiotic therapy with and without concomitant probiotic supplementation. The systematic search was performed in three databases (MEDLINE (via PubMed), Embase, and Cochrane Central Register of Controlled Trials (CENTRAL)) without filters on 15 October 2021. A random-effects model was used to estimate pooled mean differences (MD) with 95% confidence intervals (CI). This review was registered on PROSPERO (CRD42021282983). RESULTS: Of 11,769 identified articles, 15 were eligible in the systematic review and 5 in the meta-analyses. Quantitative data synthesis for Shannon (MD = 0.23, 95% CI: [(-)0.06-0.51]), Chao1 (MD = 11.59 [(-)18.42-41.60]) and observed OTUs (operational taxonomic unit) (MD = 17.15 [(-)9.43-43.73]) diversity indices revealed no significant difference between probiotic supplemented and control groups. Lacking data prevented meta-analyzing other diversity indices; however, most of the included studies reported no difference in the other reported α- and ß-diversity indices between the groups. Changes in the taxonomic composition varied across the eligible studies but tended to be similar in both groups. However, they showed a potential tendency to restore baseline levels in both groups after 3-8 weeks. This is the first meta-analysis and the most comprehensive review of the topic to date using high quality methods. The limited number of studies and low sample sizes are the main limitations of our study. Moreover, there was high variability across the studies regarding the indication of antibiotic therapy and the type, dose, and duration of antimicrobials and probiotics. CONCLUSIONS: Our results showed that probiotic supplementation during antibiotic therapy was not found to be influential on gut microbiome diversity indices. Defining appropriate microbiome diversity indices, their standard ranges, and their clinical relevance would be crucial.
背景:益生菌常用于预防抗生素引起的低多样性菌群失调,但目前尚未充分总结其在这方面的效果。我们旨在研究抗生素治疗期间同时补充益生菌对肠道微生物组组成的影响。
方法:我们对报告抗生素治疗患者与未同时补充益生菌患者之间肠道微生物多样性差异的随机对照试验进行了系统评价和荟萃分析。系统检索于 2021 年 10 月 15 日在三个数据库(MEDLINE(通过 PubMed)、Embase 和 Cochrane 对照试验中心注册库(CENTRAL))中进行,未使用过滤器。使用随机效应模型估计合并均数差(MD)及其 95%置信区间(CI)。本综述在 PROSPERO(CRD42021282983)上进行了注册。
结果:在 11769 篇确定的文章中,有 15 篇在系统评价中合格,5 篇在荟萃分析中合格。定量数据合成显示,Shannon(MD=0.23,95%CI:[-0.06-0.51])、Chao1(MD=11.59 [-18.42-41.60])和观察到的 OTUs(操作分类单元)(MD=17.15 [-9.43-43.73])多样性指数之间无显著差异。缺乏数据使得无法对其他多样性指数进行荟萃分析;然而,大多数纳入的研究报告两组之间其他报告的α和β多样性指数无差异。合格研究中分类组成的变化各不相同,但两组之间趋于相似。然而,它们显示出在 3-8 周后两组都有恢复基线水平的潜在趋势。这是迄今为止使用高质量方法进行的第一次荟萃分析和最全面的综述。本研究的主要局限性是研究数量有限且样本量小。此外,抗生素治疗的指征以及抗生素和益生菌的类型、剂量和持续时间在研究之间存在很大的可变性。
结论:我们的结果表明,抗生素治疗期间补充益生菌不会影响肠道微生物组多样性指数。定义适当的微生物组多样性指数、其标准范围及其临床相关性至关重要。
Cochrane Database Syst Rev. 2022-2-1
Cochrane Database Syst Rev. 2011-11-9
Eur J Pediatr. 2016-10
Cochrane Database Syst Rev. 2015-12-22
Cochrane Database Syst Rev. 2018-12-12
Nutrients. 2025-7-23
BMC Complement Med Ther. 2025-7-9
Front Cell Infect Microbiol. 2025-5-13
Front Plant Sci. 2022-4-19
J Gastroenterol Hepatol. 2021-12
Gut Microbes. 2021